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Abstract
  
 Based on the Basic Health Research Data of Ministry of Health's of Indonesia in 
2013, mortality rates from malignant and tumor malignancies in Indonesia are still high 
with prevalence of cancer is about 1.4%. Chemotherapy is still the primary choice in 
cancer modality that uses chemotherapeutic drugs to eradicate and inhibit the growth 
of cancer cells; however the cost this treatment is extremely high. Therefore, patient 
tends to seek alternative treatment such as consuming traditional herbal medicine for 
cancer treatment. Rutin is one of the attractive phytochemicals flavonoids because of 
its antioxidant activities. However, as traditional herbal medicine, its effectiveness is 
not yet been fully established due to the lack of scientific information. A radiotracer 
can be defined as a specific radiolabeled molecule that monitors the in vivo behaviour 
of a functional molecule, and can be used to provide biological information in a living 
system. Hence, to provide pharmacological information of rutin for cancer treatment, 
we synthesized radiolabeled flavonoid 99mTc-rutin as radiotracer. The aim of the present 
study is to develop 99mTc-rutin under varying conditions of rutin quantity, reducing agent 
concentration and incubation time. Labeling studies were performed by changing the 
selected parameters one by one and optimum labeling conditions were determined. After 
observing the conditions for maximum labeling efficiency, 99mTc-rutin was obtained with 
preparation of 700 μg of rutin with addition of 20 μg of SnCl2.2H2O as reductor and 1-3 
mCi 99mTcO4- without any incubation. Radiochemical yield of 99mTc-rutin was determined 
with radio thin layer chromatography which was found 99.28 ± 0.14% and stable up to 4 
hour. From the result of this study, the successfully labeled 99mTc-rutin can be used as a 
reference for following preclinical study. Furthermore radiolabeled 99mTc-rutin is expected 
as tools in research and development of rutin as cancer drugs from natural product to 
obtain detailed information its efficacy.  
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INTRODUCTION 
 Based on the Global Cancer Statistic 2012 
Data, mortality rates from malignant and tumour 
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malignancies in the world are still high (8.2 million 
deaths) with the prevalence of cancer is about 14.1 
million case (Torre, et al., 2015). Chemotherapy is 
still the primary choice in cancer modality that uses 
chemotherapeutic drugs to eradicate and inhibit the 
growth of cancer cells, however the cost this treat-
ment is extremely high. Therefore, the patient tends 
to seek alternative treatment such as consuming tra-
ditional herbal medicine for cancer treatment (Insti-
tute for Health Metrics and Evaluation University 
of Washington, 2017). 
 Flavonoids are a class of natural com-
pounds which have abundant availability found 
in plants, these compounds play an important role 
in the treatment of various disorders because of 
its pharmacological properties therefore it was an 
excellent source of pharmaceutical products for 
phytotherapy. Rutin (3′,4′,5,7-tetrahydroxyfla-
vone-3-rutinoside) (Figure 1) is one of the attrac-
tive phytochemicals flavonoids because of its phar-
macological activities including anti-oxidation, 
anti-inflammation, anti-diabetic, anti-adipogenic, 
neuroprotective and hormone therapy (Lambrecht, 
et al., 2010; Sharma, et al., 2013; Chua, 2013). 
Through its antioxidants activity, rutin has received 
considerable interest due to their potential roles in 
the prevention and treatment of cancer by protect-
ing cells against the effects of free radicals. Rutin 
was apparently inhibiting the process of angiogene-
sis in cancer cells where this process may stop can-
cer form new blood vessels which needed by cancer 
cells to grow and develop (Jain, et al., 2012; Dixit, 
2014). Rutin is mostly found in edible plants such 
as onions, apples, berries, tea and wine (Atanass-
ova & Bagdassarian, 2009). However, as traditional 
herbal medicine, its effectiveness is not yet been 
fully established due to the lack of scientific infor-
mation, therefore its efficacy and safety should be 
evaluated scientifically. 
 In recent years, kind of researches had re-
ported in vivo biological and pharmacological ac-
tivities of rutin. Most of the pharmacological ac-
tivities parameters of rutin have been investigated 
using conventional tools such as High Performance 
Liquid Chromatography (HPLC) and Mass Spec-
trometry (MS). However, those methods require a 
complicated process, time consuming and costly. 
Nuclear technology provides several advantages 
over conventional methods in terms of detection 
and availability sensitivity. The labeling technique 
using radioisotopes on flavonoids as radiotracer has 
been done to determine the biodistribution and phar-
macokinetic patterns in some flavonoid compounds 
(Hosseinimehr, et al., 2010; Jeon, et al., 2015; Sey-
itoglu, et al., 2009; Sriyani, et al., 2015; Xie, et al., 
2017; Choi, et al., 2016). A radiotracer can be de-
fined as a specific radiolabeled molecule that moni-
tors the in vivo behaviour of a functional molecule, 
and can be used to provide biological information 
in a living system. Therefore, the radiolabeled rutin 
as radiotracer will be useful to understanding its an-
tioxidants activity and determine their efficacy and 
effectiveness as anti-cancer.  Previous research on 
99mTc-rutin has been carried out by Bernardo, et al., 
but does not explain the optimum conditions for 
labeled rutin with technetium-99m radioisotopes 
Figure 1. Chemical structure of rutin (Djelili, et al., 2012)
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(Bernardo, et al., 2001). The present study was con-
ducted to develop 99mTc-rutin under varying condi-
tions of rutin quantity, reducing agent concentration 
and incubation time conditions for maximum label-
ing efficiency. This study will give the good prepa-
ration of 99mTc-rutin with high radiochemical yield 
for the development of 99mTc-rutin as radiotracer. 
MATERIAL AND METHODS
 The materials that used to this research were 
rutin (Sigma Aldrich, Steinheim Germany), tin(II)
chloride/SnCl2 (Sigma-Aldrich, St Louis USA), eth-
anol lichrosolv (Merck, Darmstadt Germany), am-
monium hydroxide (Merck, Darmstadt Germany), 
sodium hydroxide (Merck, Darmstadt Germany), 
hydrocloric acid (Merck, Darmstadt Germany), so-
dium chloride 0.9 % (IPHA, Bandung Indonesia), 
sterile aquabidest (IPHA, Bandung Indonesia), pH 
indicator (Merck, Darmstadt Germany), generator 
99Mo/99mTc (Polatom, Otwock Polandia), ITLC-SG 
(Agilent, Folsom USA) and TLC-SG F254 ( Merck, 
Darmstadt Germany).
 The equipment that used in this experiment 
were dose calibrator (Victoreen, Melbourne USA), 
vortex mixer, single channel analyzer (Ortec, Can-
berra Australia), and paper chromatography appara-
tus. 
Labeling of 99mTc-rutin
 Labeling of rutin with radioisotope tech-
netium-99m was performed using direct label-
ing method using SnCl2.2H2O as reducing agent. 
Some parameters were varying to obtain the opti-
mum conditions such as incubation time, amount 
of SnCl2 and rutin. The labeling process was car-
ried out by adding of SnCl2 solution (1 mg/mL HCl 
0.1 N) into the vial that contains rutin solution in 
ethanol, then incubated in room temperature for 10 
minutes. After incubation time reached, phosphate 
buffer 0.2N with pH 7.5 was added into the vial. A 
saline solution of 99mTcO4– with an activity of 1-3 
mCi was injected into the vial and its volume was 
adjusted to 1.5 mL. All experiments were carried 
out in a volume of 1.5 mL and incubation at room 
temperature.
Determination of Labeling Efficiency of 
99mTc-rutin
 The determination of labeling efficiency/
radiochemical purity of 99mTc-rutin was done us-
ing ascending paper chromatography method with 
ITLC-SG (10 × 1 cm) as the stationary phase and 
mixture of ethanol:water:ammonia (2:5:1) as the 
mobile phase to separate the impurities of 99mTc-
reduced (99mTcO2) at Rf = 0.0. While to separate the 
impurity of 99mTc-pertechnetate (99mTcO4-), using 
TLC-SG F254 (10 × 1 cm) as the stationary phase 
with NaCl 0.9 % as a mobile phase where Rf of 
99mTcO2 = 1.0. The chromatograms were dried in the 
oven at 80oC, and then every 1 cm piece of paper 
was cut and measured using Single Channel Ana-
lyzer (SCA) with NaI(Tl) detector.
 
Optimization of Reducing Agent SnCl2.2H2O
 Into five vials containing 500 µL rutin (1 
mg/mL) were added varying amount (10, 20, 30, 
40, and 50 μL) of SnCl2 (1 mg/mL) and added wa-
ter to adjust the final volume to 600 mL, then incu-
bation for 10 minutes in room temperature. After 
incubation time reached, 500 mL phosphate buffer 
0.2 N solutions with pH 7.5 were added into the 
vials. Then a solution Na99mTcO4 with an activity of 
1-3 mCi was added. The mixture was shaken with a 
vortex mixer until homogenous and then incubated 
at room temperature for 30 minutes. The optimum 
amount of reducing agent was determined from the 
labeling efficiency of 99mTc-rutin using TLC method 
as described above.This test is repeated as many as 
three times.
Optimization of Rutin Amount
 Into each vial, containing varying con-
centrations of rutin (500, 600, 700, 800, and 900 
µg/500 µL) were added the optimum SnCl2 amount 
(20 µg/20 µL) and added water to adjust the final 
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volume to 600 mL, then incubation for 10 minutes 
in room temperature. After incubation time reached, 
500 mL phosphate buffer 0.2 N solutions with 
pH 7.5 were added into the vials. Then a solution 
Na99mTcO4 with an activity of 1-3 mCi/ 400 µL was 
added. The mixture was shaken with a vortex mixer 
until homogenous and then incubated at room tem-
perature for 30 minutes. The optimum amount of 
rutin was determined from the labeling efficiency of 
99mTc-rutin using TLC method. This test is repeated 
as many as three times.
Optimization of Incubation Time
 Labeling was done by adding 20 μL of 
SnCl2 solution (1 mg/mL) into a vial containing 0.7 
mg of rutin that was dissolved in 500 µL of ethanol. 
To adjusted the final volume to 600 mL was added 
80 µL of water and then the solution was incubation 
for 10 minutes in room temperature. After the incu-
bation time reached, 1-3 mCi/400 µL of Na99mTcO4 
solution was added. The mixture was stirred gently 
until homogeneous and incubated at room temper-
ature for varying periods of time i.e., 0, 15, 30, 45, 
and 60 minutes. The optimum incubation time will 
be the time that gives a high labeling efficiency of 
99mTc-rutin. The labeling efficiency was determined 
when the intended incubation interval was reached; 
the labeling efficiency was determined using TLC 
method as described above. This test is repeated as 
many as three times.
Stability of 99mTc-rutin in Room Temperature
 The labelled compounds 99mTc-rutin that ob-
tained from the optimum conditions are as follows:
Into a vial containing 0.7 mg/500 µL of rutin solu-
tion was added 20 μL of SnCl2 solution (1 mg/mL) 
as reductor and 80 µL of water. The mixture was 
incubation for 10 minutes in room temperature. 
After the incubation time reached, 1-3 mCi/400 
µL of Na99mTcO4 solution was added. Rutin was 
successfully labelled using technetium-99m with-
out any incubation time. Stability testing was 
performed at 0, 1, 2, 3, and 4 hours after add-
ing Na99mTcO4 to see the stability of 99mTc-rutin.
Stability data was then analyzed by using bidirec-
tional ANOVA followed by Tukey analysis with 
two parameters of time and radiochemical purity.
RESULT AND DISCUSSION
 99mTc-rutin (Figure 2) have been success-
fully prepared using direct labeling method with-
Figure 2. Complexes of 99mTc-rutin prediction (Tan, et al., 2009; Zhou, et al., 2001). 
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out addition bifungctional agent. Three param-
eters which influence the labeling process have 
been varied to find the optimum labeling condition 
(Widyasari, et al., 2019).  In this study pH varia-
tions were not carried out like the previous study, 
because in this study using a phosphate buffer (pH 
7.5) which would maintain the pH of the solution 
around 7. Rutin is a flavonoid antioxidant com-
pound that is insoluble in water and the pH of the 
solution also greatly affects its solubility. At acidic 
pH the rutin solubility will decrease while at alka-
line pH there will be degradation (Jurasekova, et 
al., 2014). In addition, at neutral pH the chance of 
radiolysis will be very small.
 The identification of 99mTc-rutin labeling 
efficiency was performed by ITLC-SG with mix-
ture of ethanol, water, and ammonia (2:5:1) as the 
solvent to separate 99mTcO2 impurities (Thrall, et 
al., 1978). In this system, the colloid (99mTcO2) re-
mained in the origin but the free 99mTcO4- and 99mTc-
rutin migrated to the top. This statement difference 
with Bernardo, et al., 2001 which state that “The 
colloid migrates to the top of the strip due to its ap-
olar characteristics” (Bernardo, et al., 2001). While 
to separated free 99mTcO4- impurities using system 
TLC-SG with salin as the solvent, free 99mTcO4- im-
Figure 3. Optimization of SnCl2.2H2O amount on the labeling efficiency of 
99mTc-rutin. Labeling efficiency were 
determine using paper and thin layer chromatography with three times replications.
purities migrated to the top of the strip that the col-
loid and 99mTc-rutin remained in the origin.
 To obtained the maximum yield, the first 
parameter was varied is the amount of SnCl2.2H2O 
as reducing agent. In labeling reaction the presence 
of a reducing agent is important to decrease oxi-
dation state of  99mTc (VII) in 99mTcO4-  to produce 
99mTc complex with the ligand. The result of varia-
tion SnCl2.2H2O showed in Figure 3 and the highest 
radiochemical purity of 99mTc-rutin was reached at 
20 µg of SnCl2.2H2O with the labeling efficiency 
96.44 ± 2.07 %. Figure 3 shows that the higher 
level of SnCl2 then 20 µg make the radiochemical 
purity decreased, this is caused by the higher level 
of SnCl2 make the higher level of 99mTc-reduce im-
purities.
 The second parameter was the amount of 
rutin as a ligand. Rutin is a yellow crystalline solid 
which is insoluble in water. In this study, rutin was 
dissolved in ethanol. The optimum rutin amount in 
the labeling process was shown in Figure 4. Figure 
4 shows that the optimal rutin amount was 700 µg 
with the labeling efficiency 95.83 ± 0.90 %. Figure 
4 illustrates that radiochemical purity of 99mTc-rutin 
was stable in rutin amount higher than 700 µg, this 
is caused by that almost all technetium-99m present 
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Figure 4. Optimization of rutin amount on the labeling efficiency of 99mTc-rutin. Labeling efficiency were deter-
mine using paper and thin layer chromatography with three times replications.
Figure 5. Optimization of incubation time on the labeling efficiency of 99mTc-rutin. Labeling efficiency were deter-
mine using paper and thin layer chromatography with three times replications.
in the system has bonded with rutin so the addition 
of rutin has no effect.
 The third parameter was the optimum in-
cubation time. The optimum incubation time is the 
reaction time that results in the highest labeling ef-
ficiency. In this study, incubation was done at room 
temperature to avoid degradation of rutin as antioxi-
dant compounds. The optimum incubation time was 
shown in Figure 5. From this figure with the three 
times repetitions data, we can see that the highest 
labeling efficiency was reached just after the addi-
tion of technetium-99m and the labeling efficiency 
was not much different for up to 60 minutes.
 99mTc-rutin (Figure 2) is rutin compunds 
(Figure 1) that labeled with 99mTcO4- radioisotope 
is called labeled compounds. The stability analysis 
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Figure 6. Stability of 99mTc-rutin at room temperature (24oC). Labeling efficiency were determine using paper and 
thin layer chromatography with three times replications.
of labeled compound aim to find out information 
about how long the labeled compound were still 
good in storage. The quality of labeled compound 
is determined by the radiochemical purity. The 
good radiopharmaceuticals  are labeled compounds 
that have radiochemical purity greater than 90 % 
(Zolle, 2007). The half-life of labeled compound 
is influenced by the radioisotope that labeled that 
compound. The stability analysis of 99mTc-rutin in 
room temperature showed that until 4 hours storage 
the labeled compound still has high labeling effi-
ciency (Figure 6). In this study the stability deter-
mination of 99mTc-rutin carried for up to 4 hours, 
because the half-life of Tc-99m is 6 hours and over 
4 hours the radioactivity of 99mTc-rutin decreased 
so the radioactivity dose that must be given in pre-
clinical/clinical testing will be different. From the 
statistical analysis using ANOVA and continued 
with the Tukey analysis showing the results that 
the radiochemical purity of 99mTc-rutin from 0 to 4 
hours does not show significantly different results, 
it is shown that the labeled compounds 99mTc-rutin 
is stable up to 4 hours. The information of stability 
is required when applied in nuclear medicine.
 Rutin labeled with technetium already pub-
lished by Bernardo (Bernardo, et al., 2001)  but in 
the paper was not clearly informed the optimum 
formulation to produced 99mTc-rutin with high ra-
diochemical purity. From this study, the optimum 
formulation to produce 99mTc-rutin with high ra-
diochemical purity can be known. By obtaining 
99mTc-rutin with high radiochemical purity, it can be 
used as a radiotracer to study the effectiveness of 
rutin as an anticancer from natural compound.
CONCLUSION
 This study described the method and for-
mulation for preparation 99mTc-rutin complex. 99mTc-
rutin was successfully prepared with direct labeling 
method with labeling efficiency was 99.28 ± 0.15 
%. The optimum labeled condition obtained from 
this study was 20 µg SnCl2.2H2O as reductor, 700 
µg rutin hydrate as a ligand and without incubation 
time at room temperature. The 99mTc-rutin complex 
was stable in room temperature until 4 h after la-
beling. With this successfully to preparation 99mTc-
rutin there is an opportunity to continue to in vitro 
and in vivo study.
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